Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438023 | 1.00 | CA12 (0.40) | CA12CA1CA2CA4CA9 | |
| SCHEMBL15306146 | 0.91 | MEN1 (0.37) | CA12CA1CA2CA4CA9 | |
| SCHEMBL9924210 | 0.91 | CA12 (0.41) | CA12CA1CA2CA4CA9 | |
| SCHEMBL29438007 | 0.91 | CA12 (0.41) | CA12CA1CA2CA4CA9 | |
| SCHEMBL15303645 | 0.89 | HTR2C (0.38) | HTR2CHTR2BKMT2AMEN1PABPC1 | |
| SCHEMBL29437986 | 0.85 | HTR2C (0.34) | HTR2CHTR2BKMT2AMEN1PABPC1 | |
| SCHEMBL21116317 | 0.85 | HTR2C (0.34) | HTR2CHTR2BKMT2AMEN1PABPC1 | |
| SCHEMBL9905729 | 0.83 | AAK1 (0.38) | HTR2CHTR2BKMT2AMEN1PABPC1 | |
| SCHEMBL9924038 | 0.82 | XIAP (0.38) | HTR2CHTR2BKMT2AMEN1PABPC1 | |
| SCHEMBL19376289 | 0.81 | KMT2A (0.34) | HTR2CHTR2BKMT2AMEN1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10265316-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUCTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| US-20170273981-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2017-09-28 | — | — | US | disclosed |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-09-01 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | CA12 3602/4885CA1 1467/4885CA2 681/4885 |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | CA12 3629/4885CA1 1228/4885CA2 527/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | CA12 3602/4885CA1 1467/4885CA2 681/4885 |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | CA12 3602/4885CA1 1467/4885CA2 681/4885 |
| US-20170273981-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | CA12 3629/4885CA1 1228/4885CA2 527/4885 |
| US-10265316-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNA3, KCND3, KCNN3 | CA12 3629/4885CA1 1228/4885CA2 527/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | CA12 3629/4885CA1 1228/4885CA2 527/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | CA12 3602/4885CA1 1467/4885CA2 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.